Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR known ✓ | P00533 | 14/20 | 0.73 |
| ▸ | ERBB2 known ✓ | P04626 | 8/20 | 0.68 |
| ▸ | ABL1 known ✓ | P00519 | 2/20 | 0.67 |
| ▸ | LCK known ✓ | P06239 | 2/20 | 0.67 |
| ▸ | RET known ✓ | P07949 | 2/20 | 0.67 |
| ▸ | SRC known ✓ | P12931 | 2/20 | 0.67 |
| ▸ | KDR known ✓ | P35968 | 2/20 | 0.67 |
| ▸ | FLT3 known ✓ | P36888 | 2/20 | 0.67 |
| ▸ | JAK2 known ✓ | O60674 | 1/20 | 0.67 |
| ▸ | CHRM2 known ✓ | P08172 | 1/20 | 0.67 |
| ▸ | MET known ✓ | P08581 | 1/20 | 0.67 |
| ▸ | PDGFRB known ✓ | P09619 | 1/20 | 0.67 |
| ▸ | KIT known ✓ | P10721 | 1/20 | 0.67 |
| ▸ | CHRM1 known ✓ | P11229 | 1/20 | 0.67 |
| ▸ | BCR known ✓ | P11274 | 1/20 | 0.67 |
| ▸ | PDGFRA known ✓ | P16234 | 1/20 | 0.67 |
| ▸ | FLT1 known ✓ | P17948 | 1/20 | 0.67 |
| ▸ | PTGS1 known ✓ | P23219 | 1/20 | 0.67 |
| ▸ | OPRM1 known ✓ | P35372 | 1/20 | 0.67 |
| ▸ | FLT4 known ✓ | P35916 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1999903 | 0.99 | EGFR (0.74) | EGFRGAKFBP1ALDH1A1MAPT | |
| Hydrochloric Acid SCHEMBL643709 | 0.96 | EGFR (0.81) | EGFRGAKFBP1ALDH1A1MAPT | |
| SCHEMBL1446693 | 0.95 | EGFR (0.82) | EGFRGAKFBP1ALDH1A1MAPT | |
| SCHEMBL17967504 | 0.88 | EGFR (0.70) | EGFRGAKFBP1ALDH1A1MAPT | |
| SCHEMBL1507600 | 0.86 | EGFR (0.78) | EGFRGAKFBP1ALDH1A1MAPT | |
| Hydrochloric Acid SCHEMBL1507455 | 0.86 | EGFR (0.98) | EGFRGAKFBP1ALDH1A1MAPT | |
| SCHEMBL20865319 | 0.86 | EGFR (0.67) | EGFRGAKFBP1ALDH1A1MAPT | |
| SCHEMBL642238 | 0.85 | EGFR (0.71) | EGFRGAKFBP1ALDH1A1MAPT | |
| SCHEMBL667895 | 0.85 | EGFR (1.00) | EGFRGAKFBP1ALDH1A1MAPT | |
| SCHEMBL17858785 | 0.84 | EGFR (1.00) | EGFRGAKFBP1ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2162444-B1 | AN IMPROVED PROCESS FOR THE PREPARATION OF ERLOTINIB HYDROCHLORIDE | HETERO DRUGS LTD (IN) | 2014-06-04 | — | — | EP | disclosed |
| US-8389531-B2 | Process for erlotinib hydrochloride | HETERO DRUGS LIMITED (IN) | 2013-03-05 | — | — | US | disclosed |
| US-8343950-B2 | Cell surface tyrosine receptor kinase inhibitors; pyrogen-free; lung cancer; benign prostatic hyperplasia | CONCERT PHARMACEUTICALS, INC. (US) | 2013-01-01 | — | — | US | disclosed |
| US-7960545-B2 | Process for the prepartion of erlotinib | NATCO PHARMA LIMITED (IN) | 2011-06-14 | — | — | US | disclosed |
| US-20100130741-A1 | PROCESS FOR ERLOTINIB HYDROCHLORIDE | HETERO DRUGS LIMITED (IN) | 2010-05-27 | — | — | US | disclosed |
| EP-2162444-A2 | AN IMPROVED PROCESS FOR ERLOTINIB HYDROCHLORIDE | Hetero Drugs Limited (IN) | 2010-03-17 | — | — | EP | disclosed |
| US-20090306377-A1 | NOVEL PROCESS FOR THE PREPARTION OF ERLOTINIB | NATCO PHARMA LIMITED (IN) | 2009-12-10 | — | — | US | disclosed |
| US-20090269354-A1 | QUINAZOLINE DERIVATIVES AND METHODS OF TREATMENT | CONCERT PHARMACEUTICALS, INC. (US) | 2009-10-29 | — | — | US | disclosed |
| WO-2009121042-A1 | QUINAZOLINE DERIVATIVES AND METHODS OF TREATMENT | CONCERT PHARMACEUTICALS, INC. (US) | 2009-10-01 | — | — | WO | disclosed |
| WO-2009007984-A2 | AN IMPROVED PROCESS FOR ERLOTINIB HYDROCHLORIDE | HETERO DRUGS LIMITED (IN) | 2009-01-15 | — | — | WO | disclosed |
| US-20080166358-A1 | QUINAZOLINE DERIVATIVES AND METHODS OF TREATMENT | CONCERT PHARMACEUTICALS INC. (US) | 2008-07-10 | — | — | US | disclosed |
| WO-2008076949-A2 | QUINAZOLINE DERIVATIVES AND METHODS OF TREATMENT | CONCERT PHARMACEUTICALS INC. (US) | 2008-06-26 | — | — | WO | disclosed |
| WO-2007060691-A2 | A NOVEL PROCESS FOR THE PREPARATION OF ERLOTINIB | NATCO PHARMA LIMITED (IN) | 2007-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306377-A1 | NOVEL PROCESS FOR THE PREPARTION OF ERLOTINIB | ERBB4, ABL1, KRAS | EGFR 4/4885ERBB2 11/4885ABL1 2/4885 |
| US-20090269354-A1 | QUINAZOLINE DERIVATIVES AND METHODS OF TREATMENT | ABL1, FLT3, GRK5 | EGFR 19/4885ERBB2 4/4885ABL1 1/4885 |
| US-20080166358-A1 | QUINAZOLINE DERIVATIVES AND METHODS OF TREATMENT | ABL1, FLT3, GRK5 | EGFR 19/4885ERBB2 4/4885ABL1 1/4885 |
| US-20100130741-A1 | PROCESS FOR ERLOTINIB HYDROCHLORIDE | EGFR, KRAS, ABL1 | EGFR 1/4885ERBB2 9/4885ABL1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.